Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial
自体造血干细胞移植与阿仑单抗、奥瑞珠单抗、奥法妥木单抗或克拉屈滨治疗复发缓解型多发性硬化症的疗效和安全性比较（StarMS）：一项随机对照试验方案
期刊:BMJ Open
影响因子:2.3
doi:10.1136/bmjopen-2023-083582
Brittain, Gavin; Petrie, Jennifer; Duffy, Kate E M; Glover, Rachel; Hullock, Katie; Papaioannou, Diana; Roldan, Elisa; Beecher, Colette; Bursnall, Matthew; Ciccarelli, Olga; Coles, Alasdair J; Cooper, Cindy; Giovannoni, Gavin; Gabriel, Ian; Kazmi, Majid; Kyriakou, Charalampia; Nicholas, Richard; Paling, David; Peniket, Andy; Scolding, Neil; Silber, Eli; de Silva, Thushan; Venneri, Annalena; Walters, Stephen J; Young, Carolyn; Muraro, Paolo A; Sharrack, Basil; Snowden, John A
